U.S. Markets closed

How Athenex’s Business Segments Performed in Q1 2018

Kenneth Smith
How Athenex’s Business Segments Performed in Q1 2018

Athenex (ATNX) operates in three business segments—Oncology Innovative Platform, Global Supply Chain Platform, and Commercial Platform. Athenex’s Oncology Innovative Platform segment performs proprietary drug research and development. While the segment had incurred a net loss of $28.26 million in the first quarter of 2017, in the first quarter it generated net income of $1.51 million.